PLUS THERAPEUTICS INC
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
CNSY$0.57-11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and par value data)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,223 | $8,554 |
| Investments | 3,565 | — |
| Other current assets | 576 | 1,280 |
| Total current assets | 5,364 | 9,834 |
| Property and equipment, net | 591 | 906 |
| Operating lease right-of-use assets | 106 | 202 |
| Goodwill | 372 | 372 |
| Intangible assets, net | 513 | 42 |
| Other assets | 32 | 32 |
| Total assets | $6,978 | $11,388 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $7,912 | $6,631 |
| Operating lease liability | 68 | 120 |
| Deferred grant liability | 840 | — |
| Line of credit | 3,292 | — |
| Term loan obligation, current | — | 3,976 |
| Total current liabilities | 12,112 | 10,727 |
| Noncurrent operating lease liability | 40 | 85 |
| Deferred grant liability | — | 1,924 |
| Total liabilities | 12,152 | 12,736 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ deficit: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 6,154,758 and 5,896,333 issued and outstanding at September 30, 2024, and 4,522,656 issued and 4,444,097 outstanding as of December 31, 2023, respectively | 6 | 5 |
| Treasury stock (at cost, 258,425 and 78,559 shares as of September 30, 2024 and December 31, 2023, respectively) | (500) | (126) |
| Additional paid-in capital | 484,896 | 479,274 |
| Accumulated deficit | (489,576) | (480,501) |
| Total stockholders’ deficit | (5,174) | (1,348) |
| Total liabilities and stockholders’ deficit | $6,978 | $11,388 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.